Sitagliptin, a Selective DPP-4 Inhibitor, Improves Glycemic Control when Added to a Sulfonylurea or to a Sulfonylurea and Metformin in Patients with Type 2 Diabetes

Hermansen, Kjeld; Kipnes, Mark; Luo, Edmund; Fanurik, Debra; Khatami, Hootan; Stein, Peter P.
June 2007
Diabetes;Jun2007 Supplement 1, Vol. 56, pA143
Academic Journal
Efficacy and safety of sitagliptin (SITA) were examined in patients with type 2 diabetes and inadequate glycemic control (A1C 7.5% to 10.5%) on glimepiride (G) alone or G plus metformin (G+MF). After a titration/stabilization period on G (≥4 mg/day) ± MF (≥ 1500 mg/day) and a 2-week placebo (PBO) run-in, 441 patients (mean baseline A1C 8.3%) were randomized to the addition of SITA 100 mg q.d. or PBO for 24 weeks. Of these patients, 212 were on G alone (106 each on SITA or PBO), and 229 on G+MF (116 on SITA, 113 on PBO). The primary endpoint was A1C change from baseline for the entire cohort. After 24 weeks, the addition of SITA reduced A1C by -0.7% (p<0.001) relative to PBO (LS mean change from baseline -0.5% with SITA, +0.3% with PBO) in the entire cohort. Patients on G+MF had a PBO-subtracted A1C change from baseline of -0.9%, and patients on G alone had a PBO-subtracted change from baseline of -0.6%. For the entire cohort, SITA significantly (p<0.001) reduced fasting plasma glucose by 20 mg/dL (1.1 mmol/L) and 2-hour postprandial glucose by 36 mg/dL (2.0 mmol/L) relative to PBO at Week 24. Similar results were observed in the G alone and G+MF strata. HOMA-β was also signficantly (p<0.05) improved with SITA relative to PBO. For the entire cohort, there was a higher incidence of overall adverse experiences (AEs) (60 vs 47%) and drug-related AEs (15 vs 7%) with SITA vs. PBO, with a higher incidence of hypoglycemia AEs (12 vs 2%, respectively) contributing to these differences. At Week 24, body weight was modestly increased with SITA compared with PBO (LS mean change from baseline +0.8 vs -0.4 kg, respectively; p<0.001). In this study, dual or triple therapy with SITA added to G or G+MF improved glycemic control in the fasting and postprandial states. Since co-administration of SITA with MF has an additive effect on active GLP-1 levels (Migoya et al., ADA 2007 submitted), this may have contributed to the greater A1C efficacy observed with triple therapy (SITA with G+MF) compared to dual therapy (SITA with G). The addition of SITA was generally well tolerated; the higher rate of hypoglycemia was consistent with the degree of glycemic improvement and comparable to findings from other add-on to sulfonylurea studies.


Related Articles

  • The Effectiveness of Metformin versus Glyburide in Type 2 Diabetes: Results from ADOPT (A Diabetes Outcomes Progression Trial). Herman, William H.; Haffner, Steven M.; Kahn, Steven E.; Zinman, Bernard; Holman, Rury R.; Viberti, Giancarlo F.; Lachin, John M.; Kravitz, Barbara G.; Heise, Mark A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA146 

    ADOPT compared initial oral monotherapies in recently diagnosed type 2 diabetic patients and found rosiglitazone to be superior to metformin (Met) and glyburide (Gly) as assessed by time to monotherapy failure (MF), defined as time to the first of two successive fasting plasma glucose (FPG)...

  • Pramlintide Improved Glycemic Control and Reduced Body Weight in Patients With Type 2 Diabetes Treated With Basal Insulin (Without Mealtime Insulin) and a Thiazolidinedione. Lorenzi, Gayle; Frias, Juan; Lutz, Karen; Kesty, Nicole; Zhang, Bei; Kolterman, Orville // Diabetes;Jun2007 Supplement 1, Vol. 56, pA147 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, improves glycemic control and body weight in patients with type 2 diabetes (T2DM) treated with insulin with or without sulfonylurea (SFU) and/or metformin (MET). Its efficacy and safety as an adjunct to insulin+thiazolidinedione...

  • Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain. Hollmand, R. R. // Evidence Based Medicine;Jun2008, Vol. 13 Issue 3, p77 

    STUDY DESIGN Design: randomised controlled trial (Treating to Target in Type 2 Diabetes [4-T]). Allocation: concealed. Blinding: unblinded. STUDY QUESTION Setting: 58 centres in Ireland and the UK. Patients: 708 patients ⩾18 years of age (mean age 62 y, 64% men) who had type 2 diabetes for...

  • Diabetes treatment without weight gain.  // Pharmaceutical Technology Europe;Sep2006, Vol. 18 Issue 9, p16 

    The article reports on the presentation of the results of a clinical trial of Levemir, a novel diabetes drug, at the American Diabetes Association congress in Washington D.C. In a study of more than 1,000 people, Levemir showed promising results for diabetes control without weight gain. The drug...

  • Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus. Rajagopalan, Rukmini; Perez, Alfonso; Ye, Zhan; Khan, Mehmood; Murray, Frederick T. // Drugs & Aging;2004, Vol. 21 Issue 4, p259 

    Pioglitazone as monotherapy and in combination with sulfonylurea, metformin, or insulin has consistently demonstrated improved glycaemic and lipid parameters in patients with type 2 diabetes mellitus. Objective: We performed a subanalysis to examine the effect of pioglitazone on glycaemia and...

  • Comparative Tolerability of Sulphonylureas in Diabetes Mellitus. Harrower, A.D.B. // Drug Safety;Apr2000, Vol. 22 Issue 4, p313 

    The sulphonylurea drugs have been the mainstay of oral treatment for patients with diabetes mellitus since they were introduced. In general, they are well tolerated, with a low incidence of adverse effects, although there are some differences between the drugs in the incidence of hypoglycaemia....

  • Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Bakiner, Okan; Ertorer, Melek E.; Bozkirli, Emre; Tutuncu, Neslihan B.; Demirag, Nilgun G. // Acta Diabetologica;Mar2009, Vol. 46 Issue 1, p63 

    Aim of this prospective study is to evaluate the effect of repaglinide t.i.d. (three times a day) plus single-dose insulin glargine regimen in low-risk type 2 diabetic patients during Ramadan fasting. Participants had been taking the regimen for at least 3 months. Patients with a history of...

  • How Does Treatment Satisfaction Work? Peyrot, Mark; Rubin, Richard R. // Diabetes Care;Aug2009, Vol. 32 Issue 8, p1411 

    OBJECTIVE -- This study tested a model hypothesizing that treatment affects objective clinical outcomes, which in turn affect perceived consequences, which in turn affect satisfaction and preference judgments. RESEARCH DESIGN AND METHODS -- The model was tested in a double-blind, randomized...

  • Contraindications to the use of metformin. Jones, G C; Macklin, J P; Alexander, W D // BMJ: British Medical Journal (International Edition);1/4/2003, Vol. 326 Issue 7379, p4 

    Reports that metformin may reduce cardiovascular risks in patients with type 2 diabetes. Discussion of a United Kingdom diabetes study indicating metformin produced similar degrees of glycemic control and significantly reduced microvascular end points as did sulphonylurea and insulin; Results...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics